• Clinical Trials - Renal Cell Carcinoma

    Study Objective Contact
    A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma [LCID Study Number: 2014-043] To determine whether treatment with dalantercept plus axitinib prolongs progression free survival (PFS) compared to placebo plus axitinib in patients with advanced Renal Cell Cancer. Principal Investigator(s):
    Jacob M. Sands, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    S0931, EVEREST: EVErolimus for renal cancer ensuing surgical Therapy , A phase III study [LCID Study Number: 2014-079CIRB] The primary objective of this study is to compare recurrence-free survival in renal cancer patients randomly assigned to 54 weeks of everolimus compared to 54 weeks of placebo after full or partial removal of kidneys. Principal Investigator(s):
    Christopher G. Tretter, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras.